Dyax, taiba Pharma sales and marketing update

Dyax granted taiba's taiba ME (Dubai, UAE) exclusive rights to market Kalbitor ecallantide to treat hereditary angioedema (HAE) in the Middle East, including Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Libya and Iran. Dyax said the partners will share profits on Kalbitor sales within the territory, where taiba expects the product to be available this year. Dyax markets the subcutaneously delivered yeast-derived recombinant plasma kallikrein inhibitor in the U.S. to treat HAE. ...